The Food and Drug Administration on Wednesday granted an emergency use authorization to an at-home COVID-19 test made by German company Siemens Healthineers.
The highly contagious Delta and Omicron coronavirus variants are causing a surge in new cases across the United States, and several retailers, including CVS, Walgreens, and Walmart are limiting the number of at-home testing kits customers can purchase. The Siemens tests are expected to become available in January, and the company said its product can be used by children 2 and up as long as an adult collects the sample.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Human evolution may be responsible for autism ratesUnder the radar Neurodiversity and a complex brain may go hand in hand
-
Scientists are speeding up evolutionUnder the radar Proteins can evolve in minutes
-
A new subtype of diabetes was found and it may require different treatmentUnder the radar It is prevalent in Black Africans and Americans
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
